Aligos Therapeutics, Inc.
ALGS
$10.09
$0.252.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 210.29% | -50.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 210.29% | -50.56% | |||
| Cost of Revenue | -3.63% | -9.54% | |||
| Gross Profit | 8.32% | 7.86% | |||
| SG&A Expenses | 9.98% | -2.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.11% | -7.73% | |||
| Operating Income | 3.51% | 6.42% | |||
| Income Before Tax | -136.35% | 152.52% | |||
| Income Tax Expenses | 330.23% | 59.26% | |||
| Earnings from Continuing Operations | -136.82% | 152.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -136.82% | 152.45% | |||
| EBIT | 3.51% | 6.42% | |||
| EBITDA | 3.89% | 6.26% | |||
| EPS Basic | -129.91% | 139.19% | |||
| Normalized Basic EPS | -129.53% | 139.24% | |||
| EPS Diluted | 27.37% | 83.86% | |||
| Normalized Diluted EPS | -130.58% | 137.88% | |||
| Average Basic Shares Outstanding | 23.10% | 33.85% | |||
| Average Diluted Shares Outstanding | 18.85% | 38.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||